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Summary
Background A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic 
soft-tissue sarcoma. In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic 
soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine (an active control).
Methods We did this randomised, open-label, phase 3 study across 110 study sites in 22 countries. We enrolled 
patients aged 18 years or older with intermediate-grade or high-grade advanced liposarcoma or leiomyosarcoma who 
had received at least two previous systemic regimens for advanced disease (including an anthracycline). Using an 
interactive voice and web response system, an independent statistician randomly assigned (1:1) patients to receive 
eribulin mesilate (1·4 mg/m² intravenously on days 1 and 8) or dacarbazine (850 mg/m², 1000 mg/m², or 1200 mg/m² 
[dose dependent on centre and clinician] intravenously on day 1) every 21 days until disease progression. Randomisation 
was stratiﬁ ed by disease type, geographical region, and number of previous regimens for advanced soft-tissue sarcoma 
and in blocks of six. Patients and investigators were not masked to treatment assignment. The primary endpoint was 
overall survival in the intention-to-treat population. The study is registered with ClinicalTrials.gov, number 
NCT01327885, and is closed to recruitment, but treatment and follow-up continue.
Findings Between March 10, 2011 and May 22, 2013, we randomly assigned patients to eribulin (n=228) or dacarbazine 
(n=224). Overall survival was signiﬁ cantly improved in patients assigned to eribulin compared with those assigned to 
dacarbazine (median 13·5 months [95% CI 10·9–15·6] vs 11·5 months [9·6–13·0]; hazard ratio 0·77 [95% CI 
0·62–0·95]; p=0·0169). Treatment-emergent adverse events occurred in 224 (99%) of 226 patients who received 
eribulin and 218 (97%) of 224 who received dacarbazine. Grade 3 or higher adverse events were more common in 
patients who received eribulin (152 [67%]) than in those who received dacarbazine (126 [56%]), as were deaths (10 [4%] 
vs 3 [1%]); one death (in the eribulin group) was considered treatment-related by the investigators.
Interpretation Overall survival was improved in patients assigned to eribulin compared with those assigned to an 
active control, suggesting that eribulin could be a treatment option for advanced soft-tissue sarcoma.
Funding Eisai.
Introduction
Sarcomas are rare solid tumours that account for about 
1% of all adult malignancies. About 80% of sarcomas 
originate from soft tissue and the remaining 20% from 
bone. Together, soft-tissue sarcomas comprise a hetero-
geneous group of more than 50 diﬀ erent histological 
subtypes,1–3 with an incidence rate of two to ﬁ ve cases 
per 100 000 per year. Survival outcomes in patients with 
locally advanced, unresectable, or metastatic disease 
are poor.3–6 Treatment options for patients are scarce, 
both in number and eﬃ  cacy. First-line treatment is 
usually chemotherapy with doxorubicin, ifosfamide, or 
both.
Gemcitabine, an investigative drug in this setting, given 
alone or in combination with other drugs, has also been 
studied as a ﬁ rst-line and higher therapy in patients 
with soft-tissue sarcoma.7–9 In a randomised phase 2 
study in patients with metastatic soft-tissue sarcoma, the 
combination of gemcitabine and docetaxel was associated 
with improved progression-free survival and overall 
survival compared with gemcitabine alone, but this group 
had greater toxicity.7 Another randomised phase 2 study in 
previously treated patients with advanced soft-tissue 
sarcoma showed improved progression-free survival and 
overall survival with the combination of gemcitabine and 
dacarbazine than with dacarbazine alone.10 Second-line 
treatment options include ifosfamide, dacarbazine, 
trabectedin, or pazopanib; other drugs are occasionally 
used in speciﬁ c sarcoma subtypes despite no regulatory 
approval for this indication.2,3,11 However, outcomes with 
these drugs are generally unsatisfactory because they are 
associated with low response rates, low progression-free 
and overall survival, and the risk of treatment-limiting 
toxic eﬀ ects.3 Therefore, more eﬀ ective and tolerable 
treatment options are needed for patients with advanced 
soft-tissue sarcoma.
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Eribulin, a microtubule-dynamics inhibitor, is approved 
for metastatic breast cancer. Eribulin is a structurally 
modiﬁ ed analogue of halichondrin B, originally isolated 
from the marine sponge Halichondria okadai. Its mode of 
action is distinct from other tubulin inhibitors, and 
involves binding to speciﬁ c sites on the growing positive 
ends of microtubules to inhibit their growth.12,13 Eribulin 
also induces vascular remodelling, suppresses migration 
and invasion of cancer cells, and reverses the epithelial-
to-mesenchymal transition in many cancer cell lines.14,15 
Eribulin showed activity in a non-randomised, phase 2 
study of patients with progressive soft-tissue sarcomas 
who had previously received at most one combination 
chemotherapy or a maximum of two single drugs for 
advanced disease.16,17 In that study, 12 (32%) of 38 patients 
with leiomyosarcoma and 15 (47%) of 32 patients with 
liposarcoma (also known as adipocytic sarcoma) were 
progression-free at 12 weeks after the start of therapy, 
and eribulin was associated with a manageable 
tolerability proﬁ le.17
Based on these results, we started this randomised, 
phase 3 study to assess overall survival with eribulin or 
an active control (the cytotoxic drug dacarbazine) in pre-
treated patients with unresectable, advanced, or 
metastatic leiomyosarcoma or liposarcoma.
Methods
Study design and participants
We did this randomised, open-label, multicentre, phase 3 
study at 110 study sites in 22 countries across North 
America, Latin America, Europe, Asia, and Australia 
(appendix pp 2–10). Eligible patients were aged 18 years or 
older with histologically conﬁ rmed locally recurrent, locally 
advanced, or metastatic liposarcoma (de-diﬀ erentiated, 
myxoid or round-cell, or pleomorphic liposarcoma) or 
leiomyosarcoma. For eligibility, patients were required to 
have disease that was not amenable to curative surgery or 
radiotherapy and that was measurable according to 
Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1,18 except for the use of chest radiographs, which 
could not be used for assessment of chest lesions. Disease 
progression had to have occurred within 6 months before 
randomisation after at least two standard systemic 
regimens for advanced soft-tissue sarcoma, including an 
anthracycline (unless contraindicated). Previous use of 
adjuvant and neoadjuvant chemotherapy was allowed but 
was only considered as a line of treatment if disease 
progression had been documented within 6 months of its 
completion. Patients included had an Eastern Cooperative 
Oncology Group performance status of 0–2 and adequate 
organ function. Patients were excluded if they were 
pregnant, had received any anticancer therapy or major 
surgery within 21 days before randomisation, or had 
previously received treatment with eribulin or dacarbazine. 
All patients provided written informed consent. The 
study protocol was approved by independent ethics 
committees and all relevant institutional review boards 
for each study site.
Randomisation and masking
Patients were randomly assigned (1:1) to receive eribulin 
or dacarbazine by an independent statistician. The 
randomisation sequence was generated by computer 
according to the required speciﬁ cations, and was done 
Research in context
Evidence before this study
In 2010, when this study was designed, we did a PubMed search 
for reports with the following terms “leiomyosarcoma” OR 
“liposarcoma” OR “adipocytic sarcoma”, and ﬁ lter for “clinical 
trial, phase 3”. Only four published phase 3 studies in patients 
with leiomyosarcoma or liposarcoma were available (three of 
the four studies identiﬁ ed investigated combination regimens, 
while the fourth compared radiotherapy with observation). 
Only two of the studies included patients with liposarcoma or 
advanced or metastatic disease. Overall survival was a secondary 
endpoint in these studies (in trials in which primary and 
secondary endpoints were clearly deﬁ ned) and none of the 
studies reported a signiﬁ cant diﬀ erence in overall survival 
between the treatment groups. Median overall survival was not 
reached in one of the studies. Our more recent PubMed search 
on Oct 27, 2015, using the above search terms, identiﬁ ed three 
additional studies, one of these included updated data from the 
aforementioned study in which median overall survival was not 
reached. Two of the studies investigated combination 
regimens, and one compared monotherapy with pazopanib, 
a multitargeted tyrosine-kinase inhibitor, with placebo in 
patients with metastatic soft-tissue sarcoma. This study was 
the most comparable one to the present trial; however, it 
excluded patients with liposarcoma and its primary endpoint 
was progression-free survival. Overall survival was a secondary 
endpoint and no signiﬁ cant diﬀ erence was noted. None of the 
three studies had overall survival as a primary endpoint or 
reported a signiﬁ cant improvement in overall survival.
Added value of this study
To our knowledge, our study is the ﬁ rst randomised, phase 3 
trial of a single-agent systemic therapy with an active control to 
show a signiﬁ cant improvement in overall survival as the 
primary endpoint in patients with previously treated advanced 
leiomyosarcoma and liposarcoma. We noted a statistically 
signiﬁ cant beneﬁ t in overall survival with eribulin compared 
with the conventional cytotoxic drug dacarbazine, which was 
deemed to be clinically meaningful by the investigators.
Implications of all the available evidence
The ﬁ ndings from this study suggest that eribulin might be an 
important treatment option for patients with previously 
treated liposarcoma or leiomyosarcoma. 
For the protocol see 
http://www.uzleuven.be/
E7389-G000-309_Final_
protocol_31Jan2011.pdf
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using an interactive voice and web response system. 
Randomisation was done in blocks of six and stratiﬁ ed by 
disease type (liposarcoma or leiomyosarcoma), region 
(region one, USA and Canada; region two, western 
Europe, Australia, and Israel; or region three, eastern 
Europe, Latin America, and Asia), and number of 
previous regimens for advanced disease (two or more 
than two). The statistical function lead and study director 
were masked to treatment assignment until database 
lock and unblinding. Neither patients nor investigators 
were masked to treatment assignment.
Procedures
Eribulin mesilate was given at a dose of 1·4 mg/m² 
(equivalent to eribulin 1·23 mg/m² [expressed as free 
base]) intravenously over 2–5 min on day 1 and day 8 of 
every 21 day cycle. In case of toxic eﬀ ects, treatment was 
delayed or the dose reduced to 1·1 mg/m² or 
0·7 mg/m² (equivalent to eribulin 0·97 mg/m² or 
0·62 mg/m², respectively [expressed as free base]; 
appendix p 1).
Dacarbazine was given at a dose of 850 mg/m², 
1000 mg/m², or 1200 mg/m² as an intravenous infusion 
over 15–60 min on day 1 of every 21 day cycle. The starting 
dose was selected by the investigator based on each 
patient’s clinical status and institutional preference 
before randomisation. Haematological toxicities resulted 
in treatment delays or dose reduction, while clinically 
relevant hepatic or renal toxicity or hypersensitivity 
required treatment cessation (appendix p 1).
Tumour assessments with CT, MRI, and bone scans 
were done every 6 weeks from the date of randomisation 
for the ﬁ rst 12 weeks and every 9 weeks thereafter, or 
sooner if clinically indicated, until disease progression 
was conﬁ rmed. The follow-up period began immediately 
after the oﬀ -treatment visit, and continued as long as the 
patient was alive. The survival follow-up was done every 
12 weeks, unless the patient withdrew consent or the 
survival follow-up was terminated by the sponsor. Blood 
samples for pharmacokinetic assessments were collected 
on day 1 and day 8 of cycle one and cycle two from all 
patients receiving eribulin.
Outcomes
The primary endpoint of this study was overall survival 
from randomisation until death or last date known alive 
(censored) in all patients treated with eribulin and 
dacarbazine. The pre-speciﬁ ed secondary eﬃ  cacy 
endpoints were progression-free survival (from 
randomisation to the date of ﬁ rst documented disease 
progression or death, whichever occurred ﬁ rst), the 
number of patients who were alive and progression-free 
12 weeks from randomisation, and the number of patients 
who had clinical beneﬁ t (complete response, partial 
response, durable stable disease [≥11 weeks]). Other 
secondary outcomes were safety and tolerability of eribulin 
and dacarbazine and characterisation of the population 
pharmacokinetic proﬁ le of eribulin. Safety was assessed 
by recording and grading all adverse events using the 
Common Terminology Criteria for Adverse Events 
version 4·02,19 clinical investigations, and physical 
examinations. Protocol-speciﬁ ed exploratory endpoints 
were the proportion of patients with objective response 
(patients who had a complete or partial response), number 
of patients with disease control (deﬁ ned as complete 
response, partial response, or stable disease), duration of 
stable disease rate (proportion of patients with stable 
disease ≥11 weeks), and quality-of-life score between the 
groups, assessed using the Quality of Life Questionnaire 
(QLQ) C30 and EQ-5D questionnaires. Other planned 
exploratory analyses were the relationship between 
exposure to eribulin and pharmacodynamic biomarkers, 
eﬃ  cacy, and adverse events, and identiﬁ cation of blood 
and tumour biomarkers for safety and eﬃ  cacy endpoints.
Statistical analysis
We estimated sample size on the basis of the required 
number of target events to detect a treatment diﬀ erence 
in a comparison of overall survival. The estimated 
median overall survival in the dacarbazine group was 
projected to be 6 months on the basis of theoretical 
historical data. We considered an improvement of 
2·5 months to be of clinical importance, which translated 
Figure 1: Trial proﬁ le
Data cutoﬀ  was Jan 2, 2015. ITT=intention-to-treat. *Includes one patient who was assigned to eribulin but treated 
with dacarbazine. 
594 patients assessed for eligibility
452 randomised
228 randomly allocated to eribulin
(ITT analysis population)
224 randomly allocated to dacarbazine
(ITT analysis population)
227 received eribulin* (safety population) 223 received dacarbazine (safety population)
1 died before receiving allocated
treatment
At data cutoﬀ
44 were alive
176 had died
8 had withdrawn consent
226 discontinued eribulin
173 had progressive disease
24 had clinical progression
14 due to an adverse event
5 due to patient choice
10 due to other reasons
At data cutoﬀ
35 were alive
181 had died
8 had withdrawn consent
222 discontinued dacarbazine
165 had progressive disease
27 had clinical progression
10 due to an adverse event
10 due to patient choice
10 due to other reasons
1 did not receive dacarbazine
(withdrew consent)
142 excluded
106 did not meet inclusion criteria
36 for other reasons
See Online for appendix
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to a median overall survival of 8·5 months in patients 
assigned to eribulin and a hazard ratio (HR) of 0·71. The 
overall type 1 error was set at 0·05 assuming a two-sided 
test and power at 90%. On the basis of these assumptions, 
we estimated the event target to be 353 deaths. Assuming 
an enrolment rate of 20 patients per month, we estimated 
that we needed about 450 patients to be randomised to 
observe this number of events.
Safety monitoring was done periodically by the data 
monitoring committee (DMC) at intervals of no longer 
than 6 months, starting with the recruitment of the ﬁ rst 
patient, and as determined by the DMC. An independent 
statistical reporting team did an interim eﬃ  cacy analysis 
when 70% of events were observed. To maintain an 
overall type 1 error, we used O’Brien-Fleming stopping 
boundaries determined by means of the Lan-DeMets 
approach. With this approach, the relative α spending at 
the interim and ﬁ nal analyses at 0·7 and 1·0 information 
fraction were 0·0148 and 0·0455, respectively.
Eﬃ  cacy was assessed in all randomised patients 
(intention-to-treat population). All eﬃ  cacy endpoints 
other than overall survival were based on the tumour 
response evaluation according to RECIST 1.1.18 
A two-sided, stratiﬁ ed, log-rank test was used to compare 
the two groups for the primary endpoint of overall 
survival and all secondary eﬃ  cacy endpoints; a nominal 
signiﬁ cance value of 0·0455 (adjusted for the interim 
analysis) was used for overall survival analysis. The 
stratiﬁ cation factors included disease type (liposarcoma 
or leiomyosarcoma), geography (regions one, two, and 
three) and number of previous regimens for advanced 
disease (two or greater than two). Overall survival and 
Eribulin 
(n=228)
Dacarbazine* 
(n=224)
Median age, years (range) 56 (28–83) 56 (24–83)
<65 years 178 (78%) 178 (79%)
≥65 years 50 (22%) 46 (21%)
Sex
Male 67 (29%) 82 (37%)
Female 161 (71%) 142 (63%)
Race
White 162 (71%) 168 (75%)
Black or African-American 6 (3%) 6 (3%)
Asian† 18 (8%) 16 (7%)
Other or NA 42 (18%) 34 (15%)
Ethnic origin
Hispanic or Latino 23 (10%) 27 (12%)
Not Hispanic or Latino 170 (75%) 167 (75%)
NA 35 (15%) 30 (13%)
ECOG-PS
0 111 (49%) 90 (40%)
1 114 (50%) 121 (54%)
2 3 (1%) 13 (6%)
Geographical region
Region 1 (USA, Canada) 87 (38%) 86 (38%)
Region 2 (western Europe, 
Australia, Israel)
106 (46%) 105 (47%)
Region 3 (eastern Europe, Latin 
America, Asia)
35 (15%) 33 (15%)
Disease type
Liposarcoma 75 (33%) 78 (35%)
Leiomyosarcoma 152 (67%) 145 (65%)
Other 1 (<1%) 1 (<1%)
Liposarcoma histological subtype
De-diﬀ erentiated 32 (14%) 37 (17%)
Myxoid or round-cell 30 (13%) 26 (12%)
Pleomorphic 13 (6%) 15 (7%)
Leiomyosarcoma primary site
Uterine 68 (30%) 63 (28%)
Non-uterine 83 (36%) 82 (37%)
Unknown 1 (<1%) 0
Tumour grade
High 150 (66%) 152 (68%)
Intermediate 77 (34%) 69 (31%)
Not known 1 (<1%) 3 (1%)
Type of previous anticancer therapy
Neoadjuvant 15 (7%) 10 (4%)
Adjuvant 44 (19%) 51 (23%)
Therapeutic 224 (98%) 219 (98%)
Maintenance‡ 8 (4%) 12 (5%)
Unknown 3 (1%) 1 (<1%)
(Table 1 continues in next column)
Eribulin 
(n=228)
Dacarbazine* 
(n=224)
(Continued from previous column)
Number of previous chemotherapy regimens§
0 0 0
1 2 (1%) 3 (1%)
2 113 (50%) 103 (46%)
>2 113 (50%) 118 (53%)
Type of previous chemotherapy received in at least 5% of patients
Doxorubicin 179 (79%) 173 (77%)
Gemcitabine 119 (52%) 122 (54%)
Ifosfamide 114 (50%) 112 (50%)
Trabectedin 107 (47%) 112 (50%)
Docetaxel 97 (43%) 91 (41%)
Pazopanib 18 (8%) 17 (8%)
Investigational drugs 18 (8%) 21 (9%)
Epirubicin 13 (6%) 14 (6%)
Cisplatin 12 (5%) 13 (6%)
Cyclophosphamide 12 (5%) 9 (4%)
Data are n (%), unless otherwise indicated; due to rounding, percentages might 
not total 100. NA=not available. ECOG-PS=Eastern Cooperative Oncology Group 
performance status. *Dacarbazine was dosed at 850 mg/m², 1000 mg/m², or 
1200 mg/m² in this study, based on the investigator’s decision before 
randomisation for each patient. †Includes patients from Japan, China, and other 
Asian countries. ‡For the purposes of eligibility, maintenance therapy was 
considered therapeutic. §Including neoadjuvant and adjuvant therapy.
Table 1: Baseline patient and disease characteristics
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progression-free survival were summarised using Kaplan-
Meier estimates by treatment group and were calculated 
with two-sided 95% CIs. For all survival analyses, patients 
who were lost to follow-up and those who were alive at the 
date of data cutoﬀ  were censored at either the last date 
known alive or the date of data cutoﬀ , whichever was 
earliest. Treatment eﬀ ects were estimated by ﬁ tting a Cox 
proportional hazards model to the overall survival times 
and stratiﬁ ed as described. An additional exploratory Cox 
regression model was ﬁ tted for planned subgroup 
analysis in which the HR was stratiﬁ ed as described and, 
when applicable, with treatment as a covariate. 
Diﬀ erences in participants who were progression free at 
12 weeks, stable disease for longer than 11 weeks, and had 
clinical beneﬁ t between treatment groups were calculated 
using the Cochran-Mantel-Haenszel χ² test with the same 
strata as the primary endpoint.
The safety analysis set comprised all randomised 
patients who received at least one dose of the study 
treatment and had at least one post-baseline safety 
evaluation. Safety data were summarised separately with 
descriptive statistics. Treatment-emergent adverse events 
were described as adverse events that had an onset date of 
worsening in severity from baseline on or after the ﬁ rst 
dose of study treatment up to 30 days after the last dose.
All statistical analyses were done after the study was 
completed; the data cutoﬀ  date for analyses was 
Jan 2, 2015. Statistical analyses were done using SAS 
version 9.2. This study is registered with ClinicalTrials.
gov, number NCT01327885.
Figure 2: Overall survival (A) and progression-free survival (B)
HR=hazard ratio.
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Role of the funding source
The study was funded by Eisai and designed in 
collaboration with the principal investigator. Eisai also 
funded the data collection, data analysis, data 
interpretation, and writing of the report. DD’A and MG 
are employees of Eisai. The corresponding author had 
full access to all the data in the study, and, together with 
all authors, had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Between March 10, 2011 and May 22, 2013, we assessed 
594 patients for eligibility (ﬁ gure 1). Two patients were 
still receiving protocol treatment at the study cutoﬀ  date 
(Jan 2, 2015). The eﬃ  cacy analyses presented here are 
based on 452 patients who were randomised; 228 to 
eribulin and 224 to dacarbazine. Baseline characteristics 
were representative of a patient population with advanced 
liposarcoma or leiomyosarcoma and were largely 
balanced between the treatment groups (table 1). Most 
patients were women and younger than 65 years of age.
At the time of primary analysis, the median follow-up 
for overall survival was 31 months (IQR 25–34) for both 
treatment groups. Patients in the eribulin group had 
signiﬁ cantly longer overall survival compared with those 
in the dacarbazine group (HR 0·77; 95% CI 0·62–0·95; 
p=0·0169; ﬁ gure 2A). Median overall survival was 
13·5 months (95% CI 10·9–15·6) in the eribulin group 
and 11·5 months (9·6–13·0) in the dacarbazine group.
In several pre-speciﬁ ed subgroups, overall survival 
favoured eribulin (ﬁ gure 3; appendix p 12). Beneﬁ t with 
eribulin compared with dacarbazine seemed greater in 
patients with liposarcoma (median overall survival 
15·6 [95% CI 10·2–18·6] vs 8·4 [5·2–10·1], respectively) 
than in those with leiomyosarcoma (12·7 [9·8–14·8] vs 
13·0 [11·3–15·1]; ﬁ gure 3); however, this study was not 
powered to draw deﬁ nitive conclusions from such 
subgroup analyses.
Median progression-free survival was similar in both 
treatment groups: 2·6 months (95% CI 1·9–2·8) in the 
eribulin group and 2·6 months (1·8–2·7) in the 
dacarbazine group; and did not signiﬁ cantly diﬀ er 
between the two treatments (HR 0·88; 95% CI 0·71–1·09; 
p=0·23; ﬁ gure 2B). Also similar was the proportion of 
patients who had not progressed at 12 weeks (76 [33%, 
95% CI 27·2–39·9] patients in the eribulin group vs 64 
[29%, 22·8–35·0] in the dacarbazine group; odds ratio 1·3; 
95% CI 0·8–1·9; p=0·25) and the proportion of patients 
who had clinical beneﬁ t (105 [46%, 95% CI 39·5–52·8] vs 
107 [48%, 95% CI 41·1–54·5]; odds ratio 0·9; 
95% CI 0·7–1·4; p=0·74). No patient had a complete 
response, and a similar number of patients between 
groups had partial responses (nine [4%] in the eribulin 
group vs 11 [5%] in the dacarbazine group) or stable 
disease (119 [52%] vs 107 [48%] in the dacarbazine group). 
The proportion of patients who had an objective response 
did not diﬀ er between treatment groups (nine [4%] in the 
eribulin group vs 11 [5%] in the dacarbazine group; 
p=0·62). There were no signiﬁ cant diﬀ erences between 
the groups for participants who had disease control 
(128 [56%] patients in the eribulin group vs 118 [53%] in 
dacarbazine group; p=0·438). Duration of stable disease 
also did not diﬀ er. 96 [42%] patients in eribulin group 
and 96 (43%] in the dacarbazine group had stable disease 
for longer than 11 weeks (p=0·90). During the treatment 
period the overall health-related quality of life (Global 
Health Status scores) did not greatly diﬀ er between the 
eribulin and dacarbazine groups (appendix p 11). The 
pharmacokinetic proﬁ le of eribulin was assessed and will 
be reported elsewhere. Blood and tumour biomarkers 
and the relationship between exposure to eribulin and 
adverse events were assessed and will be reported at a 
later date.
Treatment-emergent adverse events led to study drug 
withdrawal of 17 (8%) of 226 patients in the eribulin 
safety population and 11 (5%) of 224 in the dacarbazine 
safety population; dose reduction in 58 (26%) patients 
in the eribulin safety population and 32 (14%) in the 
dacarbazine safety population; and dose interruption 
in 74 (33%) patients in the eribulin safety population 
Figure 3: Planned overall survival analyses in various patient subgroups
Overlap with the dashed line at 1 indicates no eﬀ ect. Median survival shown in appendix p 12. AJCC=American 
Joint Committee on Cancer. ECOG-PS=Eastern Cooperative Oncology Group performance status. HR=hazard ratio. 
STS=soft-tissue sarcoma. 
HR (95% CI)Events/n
Eribulin
Age group
<65 years
≥65 years
Sex
Female
Male
Previous regimens for advanced STS
2
>2
Stratification region
Region 1 (USA and Canada)
Region 2 (western Europe,
Australia, and Israel)
Region 3 (eastern Europe,
Latin America, and Asia)
Disease type
Liposarcoma
Leiomyosarcoma
AJCC sarcoma tumour grade score at diagnosis
High
Intermediate
Baseline ECOG PS
0
1
2
Previous anticancer therapy type
Anthracycline
Gemcitabine
Ifosfamide
Taxane
Trabectedin
Targeted therapy
Other
Overall
Dacarbazine
 138/178
 38/50
 124/161
 52/67
 92/121
 84/107
 63/87
 85/106
 28/35
 52/71
 124/157
 118/150
 57/77
 76/111
 97/114
 3/3
 174/225
 101/129
 108/141
 87/109
 80/108
 23/29
 66/83
 176/228
 148/178
 33/46
 110/142
 71/82
 92/122
 89/102
 69/86
 84/105
 28/33
 63/72
 118/152
 125/152
 55/69
 72/90
 97/121
 12/13
 177/219
 111/138
 115/137
 92/114
 98/116
 19/26
 70/90
 181/224
 0·73 (0·57–0·93)
 0·77 (0·45–1·32)
 0·90 (0·68–1·18)
 0·59 (0·40–0·87)
 0·90 (0·67–1·21)
 0·64 (0·47–0·88)
 0·67 (0·47–0·96)
 0·89 (0·65–1·21)
 0·67 (0·38–1·17)
 0·51 (0·35–0·75)
 0·93 (0·71–1·20)
 0·80 (0·61–1·04)
 0·65 (0·44–0·96)
 0·58 (0·41–0·82)
 1·11 (0·83–1·48)
 3·00 (0·25–35·79)
 0·77 (0·62–0·96)
 0·80 (0·60–1·07)
 0·70 (0·53–0·93)
 0·84 (0·60–1·16)
 0·64 (0·47–0·88)
 1·07 (0·53–2·16)
 0·90 (0·63–1·29)
 0·77 (0·62–0·95)
40·25 161
Favours dacarbazineFavours eribulin
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and 72 (32%) in the dacarbazine safety population. 224 
(99%) of 226 patients given eribulin and 218 (97%) of 
224 given dacarbazine had treatment-emergent adverse 
events (table 2); most of which were treatment-related 
(210 [93%] given eribulin and 203 [91%] given 
dacarbazine). The incidence of grade 3 or greater 
events was higher in the eribulin safety population 
(152 [67%]) compared with the dacarbazine safety 
population (126 [56%]). Neutropenia and leukopenia 
were more common in patients given eribulin, whereas 
anaemia and thrombocytopenia were more common in 
those given dacarbazine (table 2). The incidence of 
grade 3 or higher febrile neutropenia was low in both 
populations.
13 patients died from treatment-emergent adverse 
events (table 2). Of ten events in the eribulin safety 
population, only one (neutropenic sepsis) was 
considered by the investigators to be possibly related to 
therapy, and another event (septic shock) was 
considered to be possibly treatment-related by the 
sponsor (but not by the investigators). None of the three 
deaths in the dacarbazine safety population were 
considered by the investigators to be related to 
treatment.
In a post-hoc analysis we found that the administration 
of post-study chemotherapies was similar between the 
treatment groups (158 [69%] of 228 patients in the 
eribulin group, 141 [63%] of 224 in the dacarbazine 
group) except for the expected higher number of 
patients in the eribulin group (78 [34%]) who received 
dacarbazine outside of this trial (appendix p 1). The 
post-study use of radiotherapy and surgery was similar 
between the treatment groups (appendix p 1). Post-hoc 
analyses were done to assess overall survival by planned 
dacarbazine dose, and overall survival outcomes were 
similar irrespective of the planned dacarbazine dose 
(appendix p 11).
Discussion
This randomised, phase 3 study of a systemic therapy led 
to a signiﬁ cant improvement in its primary endpoint, 
overall survival, in patients with previously treated 
advanced leiomyosarcoma or liposarcoma. The observed 
2 month diﬀ erence in overall survival between the 
Eribulin (n=226) Dacarbazine (n=224)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Any adverse events 72 (32%) 88 (39%) 54 (24%) 92 (41%) 80 (36%) 43 (19%)
Fatigue 92 (41%) 7 (3%) 0 83 (37%) 3 (1%) 0
Nausea 89 (39%) 2 (1%) 0 105 (47%) 1 (<1%) 0
Alopecia 78 (35%) 0 0 6 (3%) 0 0
Constipation 69 (31%) 2 (1%) 0 57 (25%) 1 (<1%) 0
Pyrexia 61 (27%) 2 (1%) 0 30 (13%) 1 (<1%) 0
Anaemia 51 (23%) 14 (6%) 2 (1%) 42 (19%) 22 (10%) 5 (2%)
Asthenia 43 (19%) 3 (1%) 1 (1%) 44 (20%) 7 (3%) 0
Peripheral sensory neuropathy 42 (19%) 4 (2%) 0 8 (4%) 0 0
Decreased appetite 42 (19%) 2 (1%) 0 41 (18%) 2 (1%) 0
Abdominal pain 41 (18%) 3 (1%) 1 (<1%) 25 (11%) 8 (4%) 0
Vomiting 41 (18%) 2 (1%) 0 49 (22%) 1 (<1%) 0
Headache 41 (18%) 0 0 21 (9%) 0 0
Cough 39 (17%) 0 0 28 (13%) 0 0
Diarrhoea 37 (16%) 1 (<1%) 0 34 (15%) 1 (<1%) 1 (<1%)
Dyspnoea 31 (14%) 4 (2%) 1 (<1%) 31 (14%) 3 (1%) 2 (1%)
Back pain 31 (14%) 4 (2%) 0 28 (13%) 3 (1%) 0
Stomatitis 29 (13%) 2 (1%) 0 10 (4%) 1 (<1%) 0
Peripheral oedema 27 (12%) 0 0 16 (7%) 1 (<1%) 0
Myalgia 23 (10%) 0 0 17 (8%) 0 0
Urinary tract infection 20 (9%) 5 (2%) 0 11 (5%) 1 (<1%) 0
Neutropenia 19 (8%) 45 (20%) 35 (15%) 18 (8%) 20 (9%) 15 (7%)
Hypokalaemia 17 (8%) 6 (3%) 0 5 (2%) 3 (1%) 1 (<1%)
Leukopenia 13 (6%) 18 (8%) 5 (2%) 13 (6%) 6 (3%) 4 (2%)
Thrombocytopenia 12 (5%) 1 (<1%) 0 28 (13%) 15 (7%) 19 (8%)
Maximum grade per patient; shows grade 1–2 events that occurred in at least 10% of patients, and all grade 3 and 4 events. Fatal (grade 5) adverse events in the eribulin 
group: respiratory failure (n=2), general physical health deterioration (n=1), intestinal obstruction (n=1), large intestinal perforation (n=1), neutropenic sepsis (n=1), septic 
shock (n=1), metastases to lung (n=1), acute respiratory failure (n=1), and pneumonia aspiration (n=1); in the dacarbazine group: respiratory failure (n=1), general physical 
health deterioration (n=1), and cardiac arrest (n=1). 
Table 2: Summary of adverse events (within 30 days of last dose)
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treatment groups to favour eribulin was statistically 
signiﬁ cant and deemed to be clinically meaningful by the 
investigators.
Dacarbazine was chosen as the active comparator 
(control) in this study because it represents an acceptable 
and active treatment option in this setting after failure of 
other standard therapies, is widely available, and is 
commonly used, as shown by the high proportion of 
patients in this study who received dacarbazine after the 
study (appendix p 1). On the basis of clinical evidence 
from its use as monotherapy or in combination with 
other drugs, dacarbazine is recommended by clinical 
practice guidelines as a treatment option for advanced 
soft-tissue sarcoma.2,11 Investigators of a phase 3 study 
for trabectedin in patients with advanced soft-tissue 
sarcoma also used dacarbazine as the control drug.20 In 
the present study, we allowed three diﬀ erent dosages for 
dacarbazine to accommodate various institutional 
guidelines and investigator preferences. Our post-hoc 
analysis indicates that the diﬀ erent planned dacarbazine 
doses were associated with similar overall survival 
outcomes (appendix p 11). On the basis of similar 
historical data and in consultation with sarcoma experts, 
an overall survival of 6 months was anticipated in 
patients treated with dacarbazine in this study, at the 
time of its design in 2010. However, as in other recent 
studies,21,22 overall survival in both study groups 
surpassed initial predictions (median overall survival 
11·5 months with dacarbazine vs 13·5 months with 
eribulin), indicating that our original prediction might 
have been an underestimate.
Pre-planned subgroup analyses suggested that the 
overall survival beneﬁ t with eribulin was independent of 
age, sex, number of prior regimens for advanced disease, 
and geographic region. The overall survival outcomes 
seemed unaﬀ ected by the type of previous anticancer 
therapy. In subgroup analyses, beneﬁ t with eribulin was 
particularly strong in patients with liposarcoma 
compared with those with leiomyosarcoma; however, the 
liposarcoma subgroup was small and the study was not 
statistically powered for comparisons between the 
subgroups.
The beneﬁ t in overall survival with eribulin in this 
study was observed despite a lack of statistically 
signiﬁ cant diﬀ erences between the treatment groups in 
secondary endpoints of progression-free survival, 
participants whose tumours had not progressed at 
12 weeks, and participants with clinical beneﬁ t. A greater 
eﬀ ect of eribulin on overall survival compared with 
progression-free survival has been reported previously in 
studies in patients with metastatic breast cancer.23,24 
These data indicate that the secondary endpoints in this 
study could underestimate the eﬃ  cacy of eribulin, and 
therefore might not be an accurate predictor of overall 
survival beneﬁ t in patients with leiomyosarcoma and 
liposarcoma. The proportion of patients who received 
post-study therapy was similar between the two treatment 
arms in this study, except for the higher proportion of 
patients in the eribulin group who went on to receive 
dacarbazine after the study, as expected. However, this 
diﬀ erence is not judged suﬃ  cient to account for the 
observed beneﬁ t in overall survival with eribulin 
treatment. The positive eﬀ ect on overall survival 
compared with absence of eﬀ ect on progression-free 
survival might be attributed to the biological eﬀ ects of 
eribulin on tumour vascularisation, microenvironment, 
and metastases.14,15 The tissue samples collected from 
most patients enrolled in this study have not yet been 
analysed, and further investigation of these could help to 
show the relevance of these eﬀ ects.
Treatment-emergent adverse events were consistent 
with the known safety proﬁ les for eribulin and 
dacarbazine. Eribulin was associated with a manageable 
toxicity proﬁ le, similar to previous ﬁ ndings.17 No new or 
unexpected safety signals were noted. Most patients had 
maintained or improved quality of life, with no important 
diﬀ erences between the two treatment groups.
Our study is distinct from other recently published 
phase 3 studies in patients with soft-tissue sarcoma that 
mostly assessed combination regimens,25–27 and rarely 
used overall survival as the primary endpoint.22,25,27 
Although results from a phase 3 study comparing 
pazopanib with placebo (PALETTE; NCT00753688) were 
published in 2012, its study population excluded patients 
with liposarcoma.22 The PALETTE study also did not 
report a signiﬁ cant increase in overall survival—a 
secondary endpoint—with pazopanib compared with 
placebo.22 On the basis of the strong evidence for its use 
presented in this study, eribulin merits further 
exploration in less common subtypes of soft-tissue 
sarcoma and in earlier lines of treatment, either alone or 
in combination with other drugs, in future studies.
The absence of masking is a potential limitation of this 
study. Both quality of life and objective response rate 
were exploratory endpoints in this study. The exploratory 
nature of these endpoints might also be considered to be 
potential limitations of this study because these can 
inﬂ uence treatment decisions. However, overall survival 
is considered the gold-standard endpoint in oncology 
studies, and a 2 month survival advantage conferred by 
eribulin was statistically signiﬁ cant and deemed to be 
clinically relevant. 
In conclusion, we show that eribulin improved overall 
survival in patients with advanced soft-tissue sarcoma 
compared with an active control, dacarbazine. Our 
ﬁ ndings suggest that eribulin might be an important 
treatment option for patients with previously treated 
liposarcoma or leiomyosarcoma. 
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